Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$4.14 -0.3%	$2.91	$1.60 ▼ $15.04	$112.37M	1.84	105,460 shs	78,670 shs
SAVA Cassava Sciences	$2.31 +2.7%	$2.16	$1.15 ▼ $33.98	$108.69M	-2.05	725,855 shs	633,964 shs
TAOX Synaptogenix	$6.92 -0.6%	$0.00	$1.84 ▼ $11.98	$24.27M	1.87	273,117 shs	198,735 shs
TCRX TScan Therapeutics	$1.87 -1.1%	$1.71	$1.02 ▼ $6.23	$107.25M	0.99	231,779 shs	115,250 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	+5.22%	+19.68%	+34.25%	+51.74%	-64.45%
SAVA Cassava Sciences	+4.17%	+2.74%	-4.26%	+7.14%	-92.44%
TAOX Synaptogenix	-0.71%	0.00%	-17.24%	+695,999,900.00%	+695,999,900.00%
TCRX TScan Therapeutics	-0.53%	+12.50%	-2.07%	+30.34%	-66.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANRO Alto Neuroscience	1.8832 of 5 stars	3.3	1.0	0.0	0.0	1.1	0.0	1.3
SAVA Cassava Sciences	1.9553 of 5 stars	1.0	1.0	0.0	4.7	2.2	0.8	0.6
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	3.0988 of 5 stars	3.5	5.0	0.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	105.41% Upside
SAVA Cassava Sciences	2.00	Hold	$2.00	-13.42% Downside
TAOX Synaptogenix	0.00	N/A	N/A	N/A
TCRX TScan Therapeutics	3.00	Buy	$7.80	317.11% Upside

Current Analyst Ratings Breakdown

Latest TAOX, SAVA, TCRX, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/12/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.56 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$1.82 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.95 per share	N/A
TCRX TScan Therapeutics	$2.82M	37.63	N/A	N/A	$3.11 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	11/11/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$2.55	N/A	N/A	N/A	N/A	-66.16%	-53.11%	11/13/2025 (Estimated)
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-277.76%	-150.79%	N/A
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-1,964.88%	-63.33%	-40.19%	11/11/2025 (Estimated)

Latest TAOX, SAVA, TCRX, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A
8/14/2025	Q2 2025	SAVA Cassava Sciences	N/A	-$0.18	N/A	-$0.92	N/A	N/A
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/12/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	-$0.2848	-$0.0048	-$0.28	$1.31 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.18	18.43	18.43
SAVA Cassava Sciences	N/A	2.43	2.43
TAOX Synaptogenix	N/A	20.52	20.52
TCRX TScan Therapeutics	0.18	7.06	7.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
SAVA Cassava Sciences	38.05%
TAOX Synaptogenix	10.34%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.13%
SAVA Cassava Sciences	2.40%
TAOX Synaptogenix	2.73%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	27.08 million	24.06 million	N/A
SAVA Cassava Sciences	30	48.31 million	47.15 million	Optionable
TAOX Synaptogenix	4	3.49 million	3.39 million	N/A
TCRX TScan Therapeutics	100	56.75 million	54.28 million	Not Optionable

TAOX, SAVA, TCRX, and ANRO Headlines

Recent News About These Companies

Tocqueville Asset Management L.P. Sells 233,870 Shares of TScan Therapeutics, Inc. $TCRX

August 21, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for TCRX FY2025 Earnings?

August 19, 2025 | marketbeat.com

Lifesci Capital Issues Pessimistic Outlook for TCRX Earnings

August 19, 2025 | americanbankingnews.com

HC Wainwright Has Optimistic Outlook of TCRX FY2025 Earnings

August 17, 2025 | marketbeat.com

What is Lifesci Capital's Forecast for TCRX Q3 Earnings?

August 17, 2025 | marketbeat.com

Wedbush Cuts Earnings Estimates for TScan Therapeutics

August 17, 2025 | marketbeat.com

HC Wainwright Expects Higher Earnings for TScan Therapeutics

August 17, 2025 | americanbankingnews.com

Q3 EPS Estimates for TScan Therapeutics Cut by Wedbush

August 17, 2025 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

August 15, 2025 | marketbeat.com

TScan Therapeutics (NASDAQ:TCRX) Will Have To Spend Its Cash Wisely

August 15, 2025 | finance.yahoo.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

August 13, 2025 | marketbeat.com

TScan Therapeutics Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

August 12, 2025 | msn.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | globenewswire.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

August 5, 2025 | marketbeat.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by Brokerages

August 3, 2025 | marketbeat.com

TScan Therapeutics Elects New Directors at Annual Meeting

July 27, 2025 | theglobeandmail.com

One TScan Therapeutics Insider Raised Stake By 18% In Previous Year

July 19, 2025 | finance.yahoo.com

Tscan Therapeutics Inc News (TCRX) - Investing.com

July 9, 2025 | investing.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX, SAVA, TCRX, and ANRO Company Descriptions

Alto Neuroscience NYSE:ANRO

$4.14 -0.01 (-0.29%)

Closing price 03:59 PM Eastern

Extended Trading

$4.20 +0.06 (+1.38%)

As of 08:00 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cassava Sciences NASDAQ:SAVA

$2.31 +0.06 (+2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$2.31 0.00 (-0.22%)

As of 07:34 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Synaptogenix NASDAQ:TAOX

$6.92 -0.04 (-0.57%)

As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

TScan Therapeutics NASDAQ:TCRX

$1.87 -0.02 (-1.06%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.53%)

As of 07:05 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time